ADVERUM BIOTECHNOLOGIES INC (ADVM)
US00773U2078 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to ADVM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 40.8. This target is 270.91% above the current price.
ADVM was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about ADVM.
In the previous month the buy percentage consensus was at a similar level.
ADVM was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-19 | Chardan Capital | Reiterate | Buy -> Buy |
| 2024-03-19 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-02-06 | Mizuho | Maintains | Buy -> Buy |
| 2023-11-02 | Mizuho | Initiate | Buy |
| 2023-09-05 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-08-11 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2023-03-07 | Ladenburg Thalmann | Initiate | Buy |
| 2022-11-11 | Chardan Capital | Maintains | Neutral |
| 2022-11-11 | RBC Capital | Maintains | Sector Perform |
| 2022-08-12 | Chardan Capital | Maintains | Neutral |
| 2022-07-07 | Truist Securities | Upgrade | Hold -> Buy |
| 2021-07-23 | Chardan Capital | Maintains | Neutral |
| 2021-07-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2021-07-23 | SVB Leerink | Maintains | Market Perform |
| 2021-05-03 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-04-29 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2021-04-29 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2021-04-29 | SVB Leerink | Maintains | Outperform |
| 2021-04-29 | Truist Securities | Downgrade | Buy -> Hold |